NP
Newron Pharmaceuticals S.p.A.
NP5.DE · XETRA
8.18 € +10.54% (+0.78 €)
1M -29.67%
Market Cap 157.7M €
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
12.12 €
48.2% upside
Current Price
8.18 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NP5.DE is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
72 /100
Cheap P/FCF 4.85x
P/S 8.25x
EV/EBITDA N/A
Growth
100 /100
Growing Rev. growth 46.41%
FCF growth N/A
Book val. growth N/A
Profitability
50 /100
Moderate Net margin 69.68%
Op. margin 24.72%
FCF margin 170.01%
Quality
9 /100
Poor ROA 33.29%
Asset turnover 0.48x
ROIC 18.43%
Debt
9 /100
High Int. coverage -1.07x
Current ratio 0.76x
Net debt/EBITDA N/A
Stability
26 /100
Unstable Rev. volatility 279.55%
EPS volatility 186.12%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NP5.DE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stefan Weber
Employees
22
Headquarters
Bresso
Upcoming events
16 MAR
Earnings
Upcoming earnings report